A blood test on hospital admission showing the presence or absence of SARS-CoV-2 can identify patients at a high risk of severe COVID-19.

In Biomicrofluidics, by AIP Publishing, scientists report a membrane-based invention that can concentrate the virus content of a sample of urine or saliva, allowing it to be detected.

Researchers have demonstrated a prototype of a rapid COVID-19 molecular test and a simple-to-use, portable instrument for reading the results with a smartphone in 30 minutes.

Researchers report that tiny packages of materials released by tumors, called EVPs (extracellular vesicles and particles), may serve as biomarkers for detecting a number of different types of cancer in the early stages.

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s ongoing efforts to fight COVID-19.

A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.

Researchers reporting in ACS Nano have developed a prototype device that non-invasively detected COVID-19 in the exhaled breath of infected patients.

The findings, published in the Journal of Medical Microbiology, show the rapid molecular test called N1-STOP-LAMP, is 100% accurate in diagnosing samples containing SARS-CoV-2 at high loads.

A novel flavivirus identification test that is both fast and sensitive has been validated in Brazil by Mariana Sequetin Cunha and collaborators at the Adolfo Lutz Institute.

University of Queensland researchers have developed biosensors that use nanoengineered porous gold which more effectively detect early signs of disease, improving patient outcomes.

Testing is essential to help stop the spread of the COVID-19 virus.

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial, designed to assess the safety and efficacy of the antiviral drug DAS181, as a possible treatment for patients with severe COVID-19.

Cell biologists have developed a method for SARS-CoV-2 testing that delivers results around ten times faster than current tests.

Researchers have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood are critical indicators for the prediction of disease recurrence and disease-free survival.

Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein.